Chemically Engineered NK Cells for Cancer Immunotherapy

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61388963%3A_____%2F24%3A00602640" target="_blank" >RIV/61388963:_____/24:00602640 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/61388963:_____/24:00602646

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Chemically Engineered NK Cells for Cancer Immunotherapy

Popis výsledku v původním jazyce

The approval of chimeric antigen receptor (CAR) T cell therapies fueled the interest in the use of genetically modified immune cells in cancer therapy. Despite the enthusiasm generated especially in hemato-oncology, there are still many challenges associated with the widespread use of CAR technology. The major obstacles include the inefficient and time-consuming production associated with high costs, inefficiency in solid tumors and safety issues associated with the use of viral transduction systems. All of these and the recently initiated FDA investigations on the increased risk of T cell cancers in patients treated with CAR T products raises the need for the development of alternative approaches to their production. Such approaches enabling the production of re-engineered immune cells faster, safer and at lower price could make the adoptive cell transfer therapy accessible to a larger number of patients. The presented technology employs modified metabolic precursors, which are processed by cellular metabolic pathways to fabricate living cells containing an unnatural chemical functional group on the cell surface. This unnatural chemical groups can be subsequently used for the covalent attachment of different functional groups to cell surfaces using biocompatible chemical reaction. In this way, the methodology enables re-engineering of immune cells (e.g. NK cells) with targeting moieties that include small molecule binders, peptides, oligonucleotides, proteins, enzymes or therapeutic antibodies. These modified immune cells are more efficient in killing cancer than unmodified cells.

Název v anglickém jazyce

Chemically Engineered NK Cells for Cancer Immunotherapy

Popis výsledku anglicky

The approval of chimeric antigen receptor (CAR) T cell therapies fueled the interest in the use of genetically modified immune cells in cancer therapy. Despite the enthusiasm generated especially in hemato-oncology, there are still many challenges associated with the widespread use of CAR technology. The major obstacles include the inefficient and time-consuming production associated with high costs, inefficiency in solid tumors and safety issues associated with the use of viral transduction systems. All of these and the recently initiated FDA investigations on the increased risk of T cell cancers in patients treated with CAR T products raises the need for the development of alternative approaches to their production. Such approaches enabling the production of re-engineered immune cells faster, safer and at lower price could make the adoptive cell transfer therapy accessible to a larger number of patients. The presented technology employs modified metabolic precursors, which are processed by cellular metabolic pathways to fabricate living cells containing an unnatural chemical functional group on the cell surface. This unnatural chemical groups can be subsequently used for the covalent attachment of different functional groups to cell surfaces using biocompatible chemical reaction. In this way, the methodology enables re-engineering of immune cells (e.g. NK cells) with targeting moieties that include small molecule binders, peptides, oligonucleotides, proteins, enzymes or therapeutic antibodies. These modified immune cells are more efficient in killing cancer than unmodified cells.

Druh

O - Ostatní výsledky

CEP obor

—

OECD FORD obor

30102 - Immunology

Projekt

<a href="/cs/project/TN02000109" target="_blank" >TN02000109: Personalizovaná medicína: Translačním výzkumem k biomedicínským aplikacím</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů